Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Real-World Evidence

Real-World Evidence

                        Center for Biologics Evaluation and Research & Center for Drug Evaluation and Research Real-World Evidence Home
          Science & Research
          Science and Research Special Topics
          Real-World Evidence
          Center for Biologics Evaluation and Research & Center for Drug Evaluation and Research Real-World EvidenceReal-World Evidence Center for Biologics Evaluation and Research & Center for Drug Evaluation and Research Real-World Evidence
  
  					CBER and CDER RWE Program
	
    Share
    Post
    Linkedin

    Email
    Print**On This Page:**

Featured Activities
	Internal FDA Engagement
	Demonstration Projects
	Guidance
	Representative Publications
	Resources
	Contact Information


As defined by FDA, real-world data (RWD) are the data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources and real-world evidence (RWE) is the clinical evidence regarding a medical product’s use and potential benefits or risks derived from analysis of RWD.

Collection and analysis of RWD continue to expand in the biomedical community, accompanied by a growing understanding of RWD’s strengths and limitations. Increased availability of reliable and relevant RWD is leading to the generation of RWE that can potentially inform regulatory decisions regarding the safety and effectiveness of medical therapies. Such regulatory decisions include whether to approve a drug, what that drug’s indication(s) should be, and what safety protocols (if any) are necessary to ensure safe use of the product.

**Featured Activities**

FDA announced four additional grant awards for projects supporting the use of RWD to generate RWE in regulatory decision-making, representing the second RWE funding opportunity for U01 cooperative agreements.

To address congressional mandates and commitments, FDA issued a series of draft RWE guidances starting in 2021. There are plans for FDA to publish more in the future.

PDUFA VII commitments encourage the FDA to advance the use of RWE for use in regulatory decision-making. In particular, the Advancing RWE Program seeks to improve the quality and acceptability of RWE-based approaches in support of new intended labeling claims, including approval of new indications of approved medical products or to satisfy post-approval study requirements.

Internal FDA Engagement

The RWE Subcommittee (SC) of CDER’s Medical Policy and Program Review Council was established to serve as a cross-cutting forum for RWE issues and focuses on the evaluation of RWE and guides policy development. This multi-discipline subcommittee includes leadership and representatives from across CDER Offices, CBER, CDRH, and OCE.

Staff from the CDER, CBER, and OCE can consult with the RWE SC when evaluating the use of RWD and RWE. The RWE SC provides advisory recommendations as needed on whether underlying data, methods, and other study design elements are appropriate to provide support for a regulatory decision.  OMP’s RWE Analytics Staff serve as primary clinical advisors for RWE submissions to facilitate consistency across CDER and CBER.

Demonstration Projects

To promote shared learning and understanding with external stakeholders, FDA continues to oversee and support numerous demonstration (i.e., research) projects through multiple venues and programs including the broad agency announcements, funding opportunity announcements, CERSI grants, and inter-Agency agreements.

A list of FDA-funded RWD/RWE projects can be found on our demonstration projects.

Guidance

Framework for FDA’s Real-World Evidence Program (2018)
	Use of Electronic Health Records in Clinical Investigations (2018)
	Real-World Data: Assessing Electronic Health Records and Medical Claims Data to Support Regulatory Decision-Making for Drug and Biological Products (2021)
	Submitting Documents Utilizing Real-World Data and Real-World Evidence to FDA for Drugs and Biologics (2022)
	Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products (2023)
	Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products (2023)
	Data Standards for Drug and Biological Product Submissions Containing Real-World Data (2023)
	Real-World Data: Assessing Registries to Support Regulatory Decision-Making for Drug and Biological Products (2023)
	Digital Health Technologies for Remote Data Acquisition in Clinical Investigations (2023)Representative Publications

Oct 2023: When can real-world data generate real-world evidence
	Aug 2023: Use of Real-World Evidence in Neuroscience-Related New Drug and Biologics License Applications for Novel Therapeutics
	April 2023: Emulation of Randomized Clinical Trials with Nonrandomized Database Analyses
	May 2022: Real-World Evidence- Where Are We Now?
	July 2021: FDA approves new use of transplant drug based on RWE
	Sep 2020: Randomized, observational, interventional, and real-world-What’s in a name?
	Oct 2019: CTTI Recommendations: Use of Real-World Data to Plan Eligibility Criteria and Enhance Recruitment
	March 2019: The US FDA’s Real-World Evidence Framework: A Commitment for Engagement and Transparency on Real-World EvidenceResources

The table lists public training resources, including webinars, presentation, and workshops.

**Contact Information**

For more information on RWE, please visit the individual Center pages or contact CDERMedicalPolicy-RealWorldEvidence@fda.hhs.gov.

                                                                                  Content current as of:
      12/27/2023
              
              
Regulated Product(s)
		 Biologics
			  			     			  			     DrugsLaw(s) & Regulation(s)
			  21st Century Cures Act of 2016Real-World Evidence

          
                        Center for Biologics Evaluation and Research & Center for Drug Evaluation and Research Real-World Evidence
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop